This is the paradox at the heart of a new study that could reshape how doctors prescribe GLP-1 drugs, the blockbuster class of medications that includes Ozempic and Wegovy, to people with type 2 diabetes
Lifestyle Changes : Weight-loss success will require changes to the way you approach food and exercise
Other potential health concerns In addition to the side effects listed above, there are a few more potential risks to keep in mind if youre interested in taking Alli
Earn up to 15% back in Points with a $100+ Loyalty Rewards order
It's no wonder that, since this new class of appetite-curbing GLP-1 medications, including Ozempic, Wegovy, and Zepbound, burst into public consciousness, nearly $1 billion of venture capital dollars have been injected into the growing sector of weight-loss companies, which is now awash with startups prescribing the drugs, according to PitchBook data from the last year and a half
But for cardiovascular protection , the tone shifts: A clear role for GLP-1 receptor agonists and SGLT2 inhibitors is emerging. The 2026 report also adds full sections on: Microvascular screening: same frequency and methods as type 2 diabetes, adjusted for risk